Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 07/07/2026

    Polyomaviruses: new approaches to prevention and treatment

    In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease. Now, an international research team looking at the viral capsid has identified binding sites for neutralizing antibodies; these sites could be used to halt infection with JC polyomaviruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/polyomaviruses-new-approaches-prevention-and-treatment
  • Press release - 03/07/2026

    Vaccine Against Brain Tumors Shows Promising Long-Term Results

    A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center, Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic mutation in these tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vaccine-against-brain-tumors-shows-promising-long-term-results
  • Press release - 02/07/2026

    Virus influences rare brain lymphomas

    Primary CNS lymphomas in immunocompromised patients are among the rarest and at the same time most aggressive cancers – yet evidence-based recommendations for their diagnosis and treatment have been lacking. An international research team led by the Heidelberg Faculty of Medicine at Heidelberg University and the German Cancer Research Center has now identified characteristic imaging features of these tumors and developed a prognostic model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/virus-influences-rare-brain-lymphomas
  • Press release - 01/07/2026

    Double ERC Success for DKFZ Researchers

    Through its “Proof of Concept” (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research findings. In 2026, two scientists from the German Cancer Research Center (DKFZ) were once again selected to receive this prestigious funding: Moritz Mall and Chong Sun.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/double-erc-success-dkfz-researchers
  • Press release - 25/06/2026

    Surroundings influence developing biology of the eye

    In a virtual reality study involving zebrafish, researchers from the University of Konstanz and King’s College London have discovered that the development of the eye is influenced by what the fish see during the early stages of life – and this, in turn, alters their behaviour.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/surroundings-influence-developing-biology-eye
  • Press release - 25/06/2026

    Four Doctoral Candidates from Heidelberg University at the Lindau Nobel Laureate Meeting

    Four doctoral candidates from Heidelberg University have the opportunity to exchange ideas with outstanding scientists. They are set to take part in the 75th Lindau Nobel Laureate Meeting, which is being held in Lindau from 28 June to 3 July 2026. Jana Braunger, Tim Schubert, Laura Rueda Gensini and Nathan Trausch are among around 600 young researchers who have been selected for their outstanding academic achievements.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/four-doctoral-candidates-heidelberg-university-lindau-nobel-laureate-meeting
  • Press release - 23/06/2026

    ERC Advanced Grants for Researchers at Universität Heidelberg

    Prof. Dr Fred Hamprecht from the Interdisciplinary Center for Scientific Computing of Heidelberg University is receiving valuable funding from the ERC, which will support a project in the field of computational quantum chemistry. An ERC Advanced Grant also goes to Prof. Dr Andreas Meyer-Lindenberg, Director of the Central Institute of Mental Health and professor at the Medical Faculty Mannheim of Ruperto Carola.

    https://www.gesundheitsindustrie-bw.de/en/article/erc-advanced-grants-researchers-universitaet-heidelberg
  • Press release - 10/06/2026

    AI Diagnoses Brain Tumors in Minutes Instead of Weeks

    Experts in Heidelberg have developed an AI system that can classify brain tumors with unprecedented accuracy using standard microscopic tissue sections. Using digitized standard stains, the system identifies more than 100 molecular subtypes of central nervous system tumors, delivers results within minutes, and could accelerate the diagnosis of brain tumors worldwide.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-diagnoses-brain-tumors-minutes-instead-weeks
  • Press release - 01/06/2026

    More precise therapeutic agents for neuropsychiatry: The NMI is helping to unravel complex receptor mechanisms

    How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/more-precise-therapeutic-agents-neuropsychiatry-nmi-helping-unravel-complex-receptor-mechanisms
  • Press release - 13/05/2026

    “AI doesn't really have a clue what it's doing”

    AI is transforming science and does not stop at neuroscience. In this interview, we speak to Gabriele Lohmann about her research at the intersection of the brain and algorithms. She talks about the use of artificial intelligence as a research tool, the decoding of brain activity, and why large language models do not understand what they are doing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-doesnt-really-have-clue-what-its-doing
  • Press release - 12/05/2026

    The Silent Killer: Early Detection and Targeted Treatment of High Blood Pressure

    High blood pressure is one of the most common causes of heart attacks, strokes, kidney damage, and vascular diseases. Many people affected experience no symptoms for a long time. This is precisely why it is important to check your blood pressure regularly. To mark World Hypertension Day on May 17, the Medical Center – University of Freiburg is providing information on warning signs, diagnosis, and treatment options.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/silent-killer-early-detection-and-targeted-treatment-high-blood-pressure
  • Press release - 08/05/2026

    The Plasticity of Malignant Brain Tumors as a Potential Therapeutic Approach: Sibylle Assmus Prize for Neuro-Oncology Awarded to Moritz Mall

    The ability of cancer cells to change their identity makes tumors such as glioblastoma particularly aggressive and resistant to treatment. Moritz Mall, of the German Cancer Research Center (DKFZ) and the Hector Institute for Translational Brain Research (HITBR), is investigating how this plasticity can be specifically restricted. His approach focuses on genetic “guardians” that suppress alternative cell programs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/plasticity-malignant-brain-tumors-potential-therapeutic-approach-sibylle-assmus-prize-neuro-oncology-awarded-moritz-mall
  • Press release - 28/04/2026

    Breast cancer brain metastases: patterns in immune cells could improve therapy decisions

    Brain metastases are among the most serious complications of breast cancer. Researchers at Heidelberg University, DKFZ, and UKHD have concluded an investigation of the immune cells in the brain tissue surrounding these breast cancer brain metastases. Their findings: spatial distribution patterns of immune cells are associated with prolonged patient survival. These findings could help to guide use of immunotherapies for breast cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breast-cancer-brain-metastases-patterns-immune-cells-could-improve-therapy-decisions
  • Press release - 15/04/2026

    Why do women’s brains age differently?

    Estrogen does more than regulate reproduction — it helps brain cells handle stress. When levels decline after menopause, this ability is reduced, and these hormonal changes are believed to contribute to the increased risk of Alzheimer’s disease in women. MPI-IE researcher María José Pérez Jiménez has received the Klaus Tschira Boost Fund to investigate why — and whether these cellular responses can be restored.​

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-do-womens-brains-age-differently
  • Press release - 15/04/2026

    Pacemakers for the Brain

    Brain-computer interfaces can read neural signals and influence brain activity. We spoke with Pascal Fries about how this technology can benefit people with neurological and psychiatric conditions, future developments, and his views on ethical boundaries.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pacemakers-brain
  • Press release - 02/04/2026

    Pocket-sized biomedical technology to become smarter Volkswagen Foundation supports mobile health expert Professor Walter Karlen

    The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-biomedical-technology-become-smarter-volkswagen-foundation-supports-mobile-health-expert-professor-walter-karlen
  • Press release - 31/03/2026

    First steps towards cell therapy for brain disorders

    Researchers in Freiburg have found a way to selectively replace defective immune cells in the blood vessels of the brain using an animal model. This is an important first step towards cell therapies for Alzheimer’s disease and other brain disorders. The findings were recently published in the journal Nature Immunology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-steps-towards-cell-therapy-brain-disorders
  • Press release - 30/03/2026

    Ulm University funds projects on molecular quantum bits and digital diabetes research Research incubators focus on ideas outside the mainstream

    Creating scope for innovative projects from various disciplines: That is the aim of the research incubators at Ulm University. The aim is to initiate developments and ideas that could become relevant research areas for the University. In the current call for proposals, the jury has selected two interdisciplinary projects on quantum chemistry and digital, sensor-based diabetes research.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ulm-university-funds-projects-molecular-quantum-bits-and-digital-diabetes-research-research-incubators-focus-ideas-outside-mains
  • Press release - 23/03/2026

    Aggravated neuroimmune response, delayed wound healing Transcription factor NF-κB in astrocytes critically affects the outcome of traumatic brain injury (TBI)

    Traumatic brain injuries often lead to complications with long-lasting consequences on memory, concentration and movement control. Detrimental secondary inflammatory reactions at the injured tissue sites are often responsible for this. Researchers from Ulm have now shown that a transcription factor plays a key role in reactions to TBI. When this gene regulator is activated, an elevated neuroimmune response promotes inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/aggravated-neuroimmune-response-delayed-wound-healing-transcription-factor-nf-kb-astrocytes-critically-affects-outcome-traumatic
  • Press release - 19/03/2026

    New Approaches for Treatment-Resistant Disorders

    The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-treatment-resistant-disorders
  • Press release - 19/03/2026

    Psilocybin combined with psychotherapy shows significant efficacy in treatment-resistant depression

    The results of the EPIsoDE study show that psilocybin can have a significant antidepressant effect. It is important that its use be integrated into psychotherapeutic pre- and post-treatment care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/psilocybin-combined-psychotherapy-shows-significant-efficacy-treatment-resistant-depression
  • Press release - 12/03/2026

    Brain Diseases: Certain Neurons Are Especially Susceptible to ALS and FTD

    Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-diseases-certain-neurons-are-especially-susceptible-als-and-ftd
  • Press release - 11/03/2026

    Blood Marker for Alzheimer’s May also Be Useful in Heart and Kidney Diseases

    A certain blood protein regarded as an early indicator of Alzheimer’s disease also appears to play a role in other disorders. Researchers at DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen have found that elevated levels of phosphorylated tau protein (pTau) also occur in two lesser-known conditions that primarily affect the heart and kidneys.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-marker-alzheimers-may-also-be-useful-heart-and-kidney-diseases
  • Press release - 03/03/2026

    AI Chip Design From Heilbronn

    AI plays a huge role in the semiconductor industry, both by facilitating more efficient development processes and as a target application in development work. This is why the Fraunhofer Heilbronn Research and Innovation Centers HNFIZ are adding the Chip AI research and innovation center for AI chip design to their service range. The center is funded via the Dieter Schwarz Foundation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-chip-design-heilbronn
  • Press release - 02/03/2026

    Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros

    An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros

Page 1 / 7

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search